Actelion’s Almorexant Meets Primary Endpoint In Phase III Study
Actelion has said that the first phase III study with Almorexant (Restora 1) has met its primary endpoint – superiority of the dual orexin receptor antagonist Almorexant compared
Rocket Pharmaceuticals has entered into a credit facility agreement of up to $150m with Hercules Capital to support the ongoing development of its cardiovascular portfolio.
Ranbaxy will launch Olmesartan Medoxomil, an antihypertensive originally discovered by Daiichi Sankyo, in six African countries: Kenya, Mozambique, Nigeria, Tanzania, Uganda, and Zambia. The companies will launch the